Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase-Reference-Cited by-同舟云学术

Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase

Published:2021-06-25 Issue:4 Volume:88 Page:655-664
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Panetta John C.,Liu Yiwei,Bottiglieri Teodoro,Arning Erland,Cheng Cheng,Karol Seth E.,Yang Jun J.,Zhou Yinmei,Inaba Hiroto,Pui Ching-Hon,Jeha Sima,Relling Mary V.^ORCID

Funder

National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-021-04315-0.pdf

Reference33 articles.

1. Jarrar M, Gaynon PS, Periclou AP, Fu C, Harris RE, Stram D, Altman A, Bostrom B, Breneman J, Steele D, Trigg M, Zipf T, Avramis VI (2006) Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children’s Oncology Group study (CCG-1941). Pediatr Blood Cancer 47(2):141–146. https://doi.org/10.1002/pbc.20713

2. Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ, Ettinger AG, Ettinger LJ, Franklin J, Gaynon PS, Hilden JM, Lange B, Majlessipour F, Mathew P, Needle M, Neglia J, Reaman G, Holcenberg JS, Stork L (2002) A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood 99(6):1986–1994. https://doi.org/10.1182/blood.v99.6.1986

3. Abshire TC, Pollock BH, Billett AL, Bradley P, Buchanan GR (2000) Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 96(5):1709–1715

4. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Arkin S, Declerck L, Cohen HJ, Sallan SE (2001) Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91–01. Blood 97(5):1211–1218. https://doi.org/10.1182/blood.v97.5.1211

5. Pession A, Valsecchi MG, Masera G, Kamps WA, Magyarosy E, Rizzari C, van Wering ER, Lo Nigro L, van der Does A, Locatelli F, Basso G, Arico M (2005) Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol 23(28):7161–7167. https://doi.org/10.1200/JCO.2005.11.411

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive insight into exploring the potential of microbial enzymes in cancer therapy: Progress, challenges, and opportunities: A review;International Journal of Biological Macromolecules;2024-10

2. Metabolism of asparagine in the physiological state and cancer;Cell Communication and Signaling;2024-03-06

3. Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma;Frontiers in Pediatrics;2022-06-30

4. Asparaginase encapsulated in erythrocytes as second‐line treatment in hypersensitive patients with acute lymphoblastic leukaemia;British Journal of Haematology;2022-03-28

5. Comparison of the blood, bone marrow, and cerebrospinal fluid metabolomes in children with b-cell acute lymphoblastic leukemia;Scientific Reports;2021-10-04